Mercury Laboratories Ltd
₹780
(1.04%)
Fri, 13 Mar 2026, 02:59 am
Health Technology
Pharmaceuticals: Major
24.5KMercury Laboratories Price to Sales Ratio (P/S)
| Particulars | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 0 | 0 | 0 | 1.43 | 13.28 | 17.75 | 23.24 | 14.34 | 10.45 | 14.45 | 16.34 | 12.59 | 17.66 | 31.25 |
| Price to book ratio | 0 | 0 | 0 | 0 | 0.26 | 2.38 | 1.96 | 1.78 | 1.40 | 1.05 | 2.09 | 1.44 | 1.54 | 1.96 | 1.83 |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0.11 | 1.10 | 1 | 0.90 | 0.73 | 0.59 | 1.12 | 1 | 0.93 | 1.32 | 1.31 |
| Price to cash flow ratio | 0 | 0 | 0 | 0 | 1.36 | 0 | 46.59 | 11.53 | 9.84 | 7.21 | 10.18 | 12.27 | 32.85 | 12.69 | 27.14 |
| Enterprise value | 0 | 0 | 0 | 0 | 124.33M | 582.08M | 540.03M | 527.7M | 487.55M | 384.04M | 793.38M | 572.52M | 687.67M | 971.79M | 1.02B |
| Enterprise value to EBITDA ratio | 0 | 0 | 0 | 0 | 2.10 | 8.81 | 7.62 | 11.62 | 8.34 | 6.08 | 7.76 | 7.83 | 7.86 | 10.60 | 14.21 |
| Debt to equity ratio | 0.34 | 0.32 | 0.70 | 0.73 | 0.49 | 0.34 | 0.30 | 0.37 | 0.33 | 0.22 | 0.19 | 0.15 | 0.13 | 0.11 | 0.10 |
| Return on equity % | 0 | 25.59 | 22.62 | 23.18 | 19.75 | 19.62 | 11.67 | 7.91 | 10.26 | 10.59 | 15.50 | 9.23 | 12.98 | 11.72 | 6.02 |
Mercury Laboratories Ltd Price to Sales Ratio
The Mercury Laboratories Ltd Price to Sales Ratio is a key financial metric used by investors to evaluate Mercury Laboratories Ltd's valuation, profitability, and overall financial performance. Tracking the Mercury Laboratories Ltd Price to Sales Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Mercury Laboratories Ltd (NSE: , BSE: 538964) is currently trading at ₹780, with a market capitalization of ₹926.4M. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Mercury Laboratories Ltd Price to Sales Ratio is essential for fundamental analysis.
Mercury Laboratories Ltd Price to Sales Ratio Current Value
The current Mercury Laboratories Ltd Price to Sales Ratio stands at 1.31.
The Mercury Laboratories Ltd Price to Sales Ratio has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Mercury Laboratories Ltd Price to Sales Ratio Historical Trend
The Mercury Laboratories Ltd Price to Sales Ratio has shown the following historical trend:
- 2024: 1.31
- 2023: 1.32
- 2022: 0.93
- 2021: 1
- 2020: 1.12
The decline in Mercury Laboratories Ltd Price to Sales Ratio indicates improving financial efficiency or better earnings growth.
What Mercury Laboratories Ltd Price to Sales Ratio Indicates for Investors
The Mercury Laboratories Ltd Price to Sales Ratio plays a crucial role in understanding the company's financial health and valuation.
The P/S ratio helps evaluate valuation relative to company revenue.
Mercury Laboratories Ltd Price to Sales Ratio Analysis Summary
The Mercury Laboratories Ltd Price to Sales Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Mercury Laboratories Ltd Price to Sales Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Mercury Laboratories Ltd Price to Sales Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800